And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, once again, is rather modest. We plan to catch up on some reading, promenade with our official mascot, and hang around with a short person or two. And what about you? This remains a fine time to forage for apples and pumpkins. You could shop for a Halloween costume (feel free to write us for suggestions). You might want to mail your ballot, but make sure the ballot box is kosher. Or you could look in on someone feeling isolated. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

A World Health Organization study of more than 11,000 people in 30 countries concluded that remdesivir appeared to have little or no effect on 28-day mortality or length of hospital stays among Covid-19 patients, The New York Times writes. The data have not yet been peer-reviewed or published in a scientific journal. Gilead Sciences (GILD), which sells the drug, disputed the conclusions, noting that a variety of drugs and drug combinations had been evaluated under a wide range of circumstances and that more rigorous studies had found a benefit.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The worldwide WHO study just sounds a little screwy to me to have complete trust in the outcome conclusions. Everyone is disregarding Remedsivir now on the internet. I find it strange that a well controlled study done in the US shows benefit and now a large WHO indicates no benefit. Remdesivir is a potent antiviral. I still regard the US study as meaningful. I have some doubts about the WHO study

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy